Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study

Pichler, Petra; Claes, Nerée; Mazza, Patrizio; Żurawski, Bogdan; Potocki, Paweł; Petru, Edgar; Sediva, Marcela; Katolická, Jana; Lanza, Francesco; Fontaine, Christel

doi:10.1093/annonc/mdw390.27

Annals of Oncology

2016

DOI: 10.1093/annonc/mdw390.27

|View full text |Cite

Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study

Petra Pichler¹,

Nerée Claes

Patrizio Mazza

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2022

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…chemotherapy-induced neutropenia in adult patients with different tumor types) (13). LEOS is a prospective, noninterventional study that included patients with various tumor types treated with myelosuppressive, cytotoxic chemotherapy.…”

mentioning

confidence: 99%

The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice

Holubec

Polívka

Lisnerova

et al. 2017

View full text Add to dashboard Cite

Abstract. Febrile neutropenia (FN) is a common and potentially fatal complication of anticancer treatment, particularly in patients receiving myelosuppressive chemotherapy. It has been shown that prophylaxis with granulocyte colony-stimulating factor (G-CSF), especially itsThe vast majority of chemotherapy (CHT) regimens used in the treatment of cancer patients is burdened with hematological toxicities that can manifest by impaired cell division of white blood cells, particularly neutrophils. Effectiveness of myelosuppressive CHT is often limited by the dose-dependent toxicity, which determines the possibility of administration of additional treatment cycles (1). The risk of infectious complications significantly increases along with the decline of granulocytes below the critical level (absolute neutrophil count <500 cells/mm 3 ). Severe neutropenia (grade 3 and 4), lasting for more than three days, causes a linear increase in the risk of febrile neutropenia (FN) (10% per day). FN is a common and potentially fatal complication of anticancer treatment (2, 3). The administration of granulocyte colony-stimulating factor (G-CSF) recombinant forms results in a reduction of neutropenia and its occurrence. It has been shown that prophylaxis with G-CSF, especially its pegylated forms, significantly reduces the incidence of FN, the likelihood of chemotherapy dose intensity reduction and, also, the number of hospitalizations due to FN (4-10). Lipegfilgrastim is the newest glycopegylated modification of the original molecule filgrastim, which shows maximal structural conformity with the endogenous G-CSF. The glycopegylated form enables application of filgrastim once during the cycle of chemotherapy (11,12). This review discusses several interesting results of interim analysis from non-interventional studies evaluating the safety and efficacy of lipegfilgrastim in routine clinical practice that have been recently published. The Role of Lipegfilgrastim in Routine Clinical PracticeOne of the most interesting results in FN prophylaxis comes from the recently published interim analysis of noninterventional clinical trial LEOS (a prospective pan-European non-interventional study evaluating the effectiveness of lipegfilgrastim in clinical practice for the prophylaxis of 303 This article is freely accessible online.Correspondence to:

show abstract

mentioning

confidence: 99%

The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice

Holubec

Polívka

Lisnerova

et al. 2017

View full text Add to dashboard Cite

show abstract

Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR

Geßner¹,

Fietz

Losem

et al. 2022

Current Medical Research and Opinion

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study

Cited by 2 publications

References 0 publications

The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice

The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice

Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR

Contact Info

Product

Resources

About